TKI treatment and erectile dysfunction in men with CML
Part of Blood & lymphatic, Cancer, Heart & circulation, Kidney & urinary, Mental health clinical trials.
This study looks at whether tyrosine kinase inhibitors (TKIs), a common treatment for chronic myeloid leukemia (CML), are linked to erectile dysfunction in men. It aims to help patients and doctors understand possible side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are male and at least 18 years old, but no older than 75.
- You have chronic myeloid leukemia (CML) in the early (chronic) phase.
- You started your first TKI treatment between January 2015 and January 2022.
- You did not have erectile dysfunction before starting TKI therapy.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial looks at how gut bacteria affect the way chronic myeloid leukemia (CML) patients respond to tyrosine kinase inhibitor (TKI) medications. It may help doctors understand why some people have better outcomes than others.
This study tracks the experiences and health outcomes of people with chronic myeloid leukemia (CML) who are taking approved first or second line tyrosine kinase inhibitor (TKI) medicines. It helps doctors learn how these treatments work in everyday care.
This study looks at how TKI medications, used to treat chronic myeloid leukemia (CML), may affect thyroid function. It will track patients starting TKI therapy to see if thyroid problems develop.
This study tests whether tadalafil, a daily pill for erectile dysfunction, improves blood vessel health and erectile function. It may help men with erectile dysfunction caused by blood vessel problems.
This study examines whether a new type of cancer medication affects thinking, memory, and focus in people with chronic myeloid leukemia (CML) or chronic lymphocytic leukemia (CLL). Researchers will compare people starting this medication with healthy volunteers to understand any changes.
This trial tests an experimental drug called TGRX-678 for people with a specific, more advanced stage of chronic myeloid leukemia (CML) called 'accelerated phase.' It’s for patients whose cancer has stopped responding to or who couldn't tolerate earlier targeted therapies (tyrosine kinase inhibitors).
Hear when a new Tyrosine Kinase Inhibitor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.